Baird Raises Qiagen (QGEN) Price Target to $52
Key Points
- Baird reaffirmed its Outperform rating on Qiagen N.V. on October 22, 2026, while raising its price target to $52 from $50.
- Baird's $52 price target implies 4% upside from Qiagen N.V.'s ($QGEN) current $50 share price.
- Qiagen recently traded around $50.00, sitting well above its 50-day moving average of $44.14 ahead of its November 4, 2026 earnings report.
- Wall Street maintains a consensus buy rating on the healthcare diagnostics firm, backed by 12 analyst opinions.
Get Qiagen N.V. text alerts
We text you when insiders, Congress, analysts or big funds move on $QGEN.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Qiagen N.V. alert may contain errors. Disclosures
On October 22, 2026, Baird reaffirmed its Outperform rating on Qiagen N.V. (NYSE: QGEN) while lifting its price target to $52 from $50. According to the research note released on October 22, 2026, the firm expressed a positive outlook on the healthcare diagnostics company, moving its expected value higher from the previous $50 target.
QGEN
Qiagen N.V.
Baird vs. the S&P 500
Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.
Baird's Call on Qiagen N.V.
Baird's decision to keep an Outperform rating comes alongside recent moves from other major financial firms. On September 9, 2026, UBS maintained a Neutral rating while lowering its target from $52 to $47. Later, on October 6, 2026, Barclays upgraded the stock to Overweight and boosted its price target to $55 from $40. JP Morgan maintained an Overweight rating on October 14, 2026, lifting its target to $55 from $50, before adjusting its stance on October 22, 2026, by moving to a Neutral rating with a $52 target. Across the broader analyst community, Qiagen holds a consensus buy rating with a mean price target of $48.64 based on 12 opinions.
Other Institutional Activity in Qiagen N.V.
Principal Financial Group, Inc. grew its holdings by 6,643,158 shares, ending with 6,648,681 shares worth about $334.3 million. Earnest Partners LLC grew its holdings by 704,858 shares, ending with 4,573,455 shares worth about $230.0 million. Millennium Management Llc grew its holdings by 3,247,765 shares, ending with 3,845,605 shares worth about $193.4 million.
Qiagen N.V. Stock Holds Steady
Qiagen shares recently traded around $50.00 as of October 22, 2026, down about 0.6% from their event-day close of $50.28. The stock trades comfortably above its 50-day moving average of $44.14 and its 200-day moving average of $42.50. The company has a market capitalization of roughly $10.4 billion and a trailing P/E ratio of 25.5.
$QGEN price target
Qiagen N.V. daily closes and this analyst's $52 target. Not advice.
Recent Earnings
For the trailing twelve months, Qiagen reported revenue of $2.10 billion and earnings of $1.97 per share. The company posted a net profit margin of 19.5% and a return on equity of 11.9%. Investors look toward the company's next earnings report on November 4, 2026.
Dividend
Qiagen pays an annual dividend rate of $0.35 per share, giving it a dividend yield of 0.7% with a payout ratio of 17.8%.
About Qiagen N.V.
Headquartered in Venlo, Netherlands, Qiagen provides sample-to-insight solutions that transform biological samples into molecular insights for customers worldwide. The company supports molecular testing, diagnostics, and academic research through its specialized tools and technologies. This ongoing research activity helps shape how institutional investors and analysts evaluate the firm's growth potential.
Bottom Line
Baird's updated target highlights confidence in the diagnostics provider as shares hover near recent highs. Investors should watch for the upcoming earnings report on November 4, 2026, for fresh details on revenue growth and profit margins.
Related Filing Alerts
Source: Baird's rating change on $QGEN (Oct 22, 2026). Written by software, not financial advice. How we make alerts